Target intelligence / Profile preview

Histone deacetylase 1, 2, 3, and 8 (HDAC1, HDAC2, HDAC3, HDAC8)

Target
HDAC1, HDAC2, HDAC3, HDAC8
Molecular classification
Enzyme, Histone deacetylase, Histone modification, Epigenetic regulator, Class I histone deacetylase
01

Overview

Histone deacetylases 1, 2, 3, and 8 are zinc-dependent enzymes belonging to Class I histone deacetylases. They catalyze the removal of acetyl groups from the lysine residues on the N-terminal tails of core histones, leading to chromatin condensation and transcriptional repression. These enzymes play a pivotal role in the regulation of gene expression, epigenetic silencing, and cellular differentiation. Their dysregulation is implicated in various diseases, notably cancer, making them important targets for small-molecule inhibitors. In addition to histone substrates, Class I HDACs also deacetylate several non-histone proteins, influencing diverse cellular processes including cell cycle, apoptosis, and DNA repair.

Other names
For HDAC1: RPD3For HDAC1: GON-10For HDAC2: RPD3For HDAC2: YAF1For HDAC2: YAF2For HDAC3: SMAP45For HDAC3: SMAPFor HDAC8: null (HDAC8 is the standard name)HDAC family members may also be referred to as Class I histone deacetylases
02

Mechanism of action

Inhibition of histone deacetylase activity Induction of histone hyperacetylation Reactivation of silenced genes (including tumor suppressors) Promotion of cell cycle arrest and apoptosis in cancer cells Modulation of immune response

03

Biological functions

Regulation of gene expression via chromatin remodelingEpigenetic silencingTranscriptional repressionCell cycle progressionCell proliferationRegulation of apoptosisRegulation of non-histone protein function
04

Disease associations

Cancer (overexpression linked to oncogenesis)Neurodegenerative diseasePsychiatric disorderFibrotic diseaseCardiovascular disease
05

Safety considerations

Off-target effects due to inhibition of multiple HDAC isoformsHematologic toxicities (thrombocytopenia, neutropenia)Cardiac arrhythmias (QT prolongation)Gastrointestinal symptoms (nausea, vomiting, diarrhea)FatigueRisk of infections due to immunomodulation
06

Interacting drugs

Vorinostat (SAHA)

7 more in the full profile.

07

Biomarkers

HDAC1, HDAC2, HDAC3, or HDAC8 expression levels (by immunohistochemistry or transcript quantification)Histone acetylation statusTumor sensitivity to HDAC inhibitorsAcetylation levels of p21, α-tubulin, or other non-histone proteins

Beyond the preview

Go deeper on Histone deacetylase 1, 2, 3, and 8 (HDAC1, HDAC2, HDAC3, HDAC8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone deacetylase 1, 2, 3, and 8 (HDAC1, HDAC2, HDAC3, HDAC8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call